Response to uxolitinib in Vitiligo in Adults and Adolescents.

Published Date: 29 Jul 2023

A subset of adolescents receiving topical JAK inhibitor therapy for vitiligo responses were assessed using pooled data from the phase 3 TRuE-V1 and TRuE-V2 studies.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot